Rosiglitazone promotes ENaC-mediated alveolar fluid clearance in acute lung injury through the PPAR?/SGK1 signaling pathway.

ABSTRACT:

Background

Pulmonary edema is one of the pathological characteristics of acute respiratory distress syndrome (ARDS). The epithelial sodium channel (ENaC) is thought to be the rate-limiting factor for alveolar fluid clearance (AFC) during pulmonary edema. The peroxisome proliferator-activated receptor ? (PPAR?) agonist rosiglitazone was shown to stimulate ENaC-mediated salt absorption in the kidney. However, its role in the lung remains unclear. Here, we investigated the role of the PPAR? agonist in the lung to find out whether it can regulate AFC during acute lung injury (ALI). We also attempted to elucidate the mechanism for this.

Methods

Our ALI model was established through intratracheal instillation of lipopolysaccharide (LPS) in C57BL/6?J mice. The mice were randomly divided into 4 groups of 10. The control group underwent a sham operation and received an equal quantity of saline. The three experimental groups underwent intratracheal instillation of 5?mg/kg LPS, followed by intraperitoneal injection of 4?mg/kg rosiglitazone, 4?mg/kg rosiglitazone plus 1?mg/kg GW9662, or only equal quantity of saline. The histological morphology of the lung, the levels of TNF-? and IL-1? in the bronchoalveolar lavage fluid (BALF), the level of AFC, and the expressions of ?ENaC and serum and glucocorticoid-induced kinase-1 (SGK1) were determined. Type 2 alveolar (AT II) cells were incubated with rosiglitazone (15??M) with or without GW9662 (10??M). The expressions of ?ENaC and SGK1 were determined 24?h later.

Results

A mouse model of ALI was successfully established. Rosiglitazone significantly ameliorated the lung injury, decreasing the TNF-? and IL-1? levels in the BALF, enhancing AFC, and promoting the expressions of ?ENaC and SGK1 in ALI mice, which were abolished by the specific PPAR? blocker GW9662. In vitro, rosiglitazone increased the expressions of ?ENaC and SGK1. This increase was prevented by GW9662.

Conclusions

Rosiglitazone ameliorated the lung injury and promoted ENaC-mediated AFC via a PPAR?/SGK1-dependent signaling pathway, alleviating pulmonary edema in a mouse model of ALI.

SUBMITTER: He J 

PROVIDER: S-EPMC6540532 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature